Gemfibrozil

CHEMBL457 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
250.3 g/mol
LogP
3.8
Phase
4

A fibrate medication used to lower triglyceride levels and raise HDL (good) cholesterol by activating receptors in the liver that regulate fat metabolism. It is used in patients at risk for cardiovascular disease or pancreatitis due to very high triglycerides, and may also benefit patients with chronic kidney disease affecting lipid levels. Regular monitoring of liver function and muscle-related symptoms is recommended during treatment.

Molecular Weight

250.3300 g/mol

LogP

3.80

TPSA

46.50 Ų

Lipinski RO5

Pass

Therapeutic Areas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1

InChI

InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)

Molecular Formula

C15H22O3

HBD / HBA

1 / 3

Rotatable Bonds

6

Heavy Atoms

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A fibrate medication used to lower triglyceride levels and raise HDL (good) cholesterol by activating receptors in the liver that regulate fat metabolism. It is used in patients at risk for cardiovascular disease or pancreatitis due to very high triglycerides, and may also benefit patients with chronic kidney disease affecting lipid levels. Regular monitoring of liver function and muscle-related symptoms is recommended during treatment.

Yes, Gemfibrozil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL457. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3463. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.